

Suzette Girgis, BPharm, MS, PhD
Vice President, Jazz Pharmaceuticals
(609) 903-8202 – sgirgis@jazzpharma.com
[linkedin.com/in/suzette-girgis/](https://www.linkedin.com/in/suzette-girgis/)

Profile:

A patient centric clinical pharmacology executive with a distinct combination of strategic, scientific, operational, and management experience spanning various stages of compound development from discovery to commercialization. A creative and rational thinker with innovative mindset and a solid track record of producing results in a matrix-based environment with passion for talent development. Highly competent at analyzing complex business goals and scientific problems and conveying them into clear objectives that drive skilled teams to perform at their best and deliver value

Education:

- PhD, Pharmaceutical Sciences (PK/PD), University of Rhode Island, Dec 1999
- MS, Applied Pharmaceutical Sciences, University of Rhode Island, May 1997
- BPharm, Pharmacy, Cairo University, May 1992

Positions Held:

- **Jazz Pharmaceuticals Research & Development: Oct 2022 - present**
 - VP & Head Global Clinical Pharmacology & Pharmacometrics
- **Johnson & Johnson, Janssen Research & Development (JNJ): May 2008 – Oct 2022**
 - Head, Hematologic Malignancies, Clinical Pharmacology & Pharmacometrics (CPP)
 - Compound Development Team Leader (CDTL), Oncology Bench Program, 2017
 - US Head of Scientific & Technical Operations, Clinical Pharmacology Small Molecule (CPSM)
 - Director, Clinical Pharmacology leader, CPSM
- **Bristol Myers Squibb Research & Development (BMS): Oct 2003- May 2008**
 - Associate Director, Discovery Medicine & Clinical Pharmacology
 - Senior Research Investigator, Oncology/Immunology, Clinical Discovery
- **Schering-Plough Research Institute (SPRI) now Merck: Jul 2000 – Oct 2003**
 - Associate Principal Scientist, Drug Metabolism & Pharmacokinetics
 - Senior Scientist, Drug Metabolism & Pharmacokinetics
- **Johnson & Johnson, Janssen Research Foundation, Postdoctoral Fellow, Clinical Pharmacokinetics, 2000**

Industry Experience:

- Strong drug development experience (20+ years) in biologics, cell therapy, and small molecule at early and late stage of development, including filing and registration
- Significantly contributed to various compounds strategies and submissions through leading/overseeing the development & execution of clinical pharmacology strategy, evidence-driven analyses, and related submission documents (Rylaze, Tecvayli, Carvykti, Darzalex, Velcade, Dacogen, Nulojix and Orelncia)
- Solid experience in dose selection: starting dose for First in Human (including translational experiments) and the dose regimen for Proof-of-Concept (teclistamab, talquetamab, CD22XCD3, MALT1, BTKi)
- Extensive and positive interactions with health authorities (IND/CTA, EOP1 & 2, NDA/BLA/MAA, and post-marketing)
- Led the translational work on soluble BCMA in multiple myeloma bispecific and CART programs
- Extensive experience with preclinical, drug metabolism and clinical development in oncology [JNJ & BMS (both heme & solid tumor)], immunology [BMS: belatacept, abatacept & p38], cardiovascular/metabolic diseases [SPRI (ezetimibe & integrilin) & BMS (apixaban, saxagliptin & dapagliflozin)], neuroscience [JNJ (TRPM8, JNJ-26489112, stroke cell therapy)] and infectious disease [SPRI (CCR5)]
- Innovative thinker, efficiently apply Model-informed Drug Development strategy to improve and accelerate decision making, including PK/PD, translational and disease models, physiologically-based PK (PBPK), and quantitative system pharmacology (QSP)

- Led the preclinical PK/PD activities of immuno-oncology compounds [CD3 redirector projects before and after NME declaration (BCMA, GPRC5D, PSMA), CD40 and listeria LADD immunotherapies]
- Deep understanding of global development process, disease interception, precision medicine, competitive intelligence, target product profile, market access, commercialization, pricing strategies, and publication plans
- Deep understanding of disease pathophysiology and quantitative pharmacology
- Solid knowledge of optimizing clinical strategy, combination regimens, indications sequencing, and life cycle management
- Significant collaboration with discovery, DMPK, bioanalytical, toxicology, clinical, biomarkers, safety, biostatistics, regulatory, CMC, and commercial colleagues to identify potential issues and contingency planning to enable global product registration
- Effective communicator across scientific functions and business stakeholders to ensure alignment around development strategy and milestones.
- Extensive collaboration with external KOLs, academic institutions, and partnering companies
- Promote innovation, safe and transparent environment
- Experience with operational activities, budget management, planning, resource allocation, outsourcing and CRO oversight
- Strong Due Diligence activities and business development assessments (translational, dose selection, and development strategy)
- Solid managerial and mentoring skills
- Jazz Pharmaceuticals R&D Leadership team member

Recent Extracurricular Activities:

- Invited Speaker at Sino-American Pharmaceutical Professionals Association (SAPA-GP), Model-informed Drug Development in Oncology, April 2023
- Invited Speaker at American Conference on Pharmacometrics (ACoP), Dose Justification Strategy for Teclistamab, Oct 2022
- Invited Speaker at BCMA targeted therapies Summit, Teclistamab Journey from Discovery to Filing, July 2022
- Speaker at American Association of Pharmaceutical Scientists (AAPS), Development of T cell Dependent Therapies with SC Delivery, Oct 2021
- Invited lecturer at Ernest Mario School of Pharmacy, Rutgers University
- JNJ Quantitative Sciences TED Talk co-chair, 2019
- Speaker at the Advances in Immuno-Oncology USA Congress (Clinical/Translational), Oct 2018

Professional Membership:

- Member of the American College of Clinical Pharmacology (ACCP)
- Member of the American Society for Clinical Pharmacology & Therapeutics (ASCPT)
- Member of the American Society of Clinical Oncology (ASCO)
- Member of the American Society of Hematology (ASH)
- ACCP Membership Committee 2023
- AAPS: Pharmacokinetics, Pharmacodynamics and Drug Metabolism Section (PPDM), Abstract Screening Committee, multiple years
- ASCPT: Abstract Screening Committee, 2020

Modeling Skills:

- Pharmacokinetic/pharmacodynamic modeling: NONMEM, Phoenix/WinNonlin, Kinetica, STELLA, SAAM II

Selected Manuscripts:

- **S. Girgis**, S X. Wang Lin, K. Pillarisetti, R. Verona, D. Vieyra, T. Casneuf, D. Fink, X. Miao, Y. Chen, T. Stephenson, A. Banerjee, B. Hilder, J. Russell, J. Infante, Y. Elsayed, J. Smit, J D. Goldberg. "Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma", Blood Advances, Feb 2023
- Chari, M C. Minnema, J G. Berdeja, A. Oriol, N W. van de Donk, P. Rodríguez-Otero, E. Askari, M V. Mateos, L J. Costa, J. Caers, R. Verona, **S. Girgis**, S. Yang, R. Goldsmith, K. Pillarisetti, B. Hilder, J. Russell, J D. Goldberg, A. Krishnan. "Talquetamab, a T Cell Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma", New England Journal of Medicine, Dec 2022
- V. Moreno, R. Perets, T. Peretz, N. Fourneau, **S. Girgis**, Y. Guo, P. Hellemans, R. Verona, N. Pendás, Q. Xia, R. Geva, E. Calvo. "A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors", Investigational New Drugs, Dec 2022
- **S. Girgis**, S X. Wang Lin, K. Pillarisetti, A. Banerjee, T. Stephenson, X. Ma, S. Shetty, TY. Yang, B. Hilder, T. Jiao, B. Hanna, H. Adams, YN. Sun, A. Sharma, J. Smit, J. Infante, J D. Goldberg, Y. Elsayed. "Translational approach of using ex vivo cytotoxicity and early clinical data to predict Teclistamab efficacious therapeutic range in multiple myeloma patients", Target Oncology, June 2022
- P. Moreau, S. Usmani, A. Garfall, N W. van de Donk, H. Nahi, J F. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosinol, A. Chari, L. Karlin, L. Benboubker, M V. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, **S. Girgis**, S X. Wang Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, R V. Rampelbergh, A. Banerjee, J D. Goldberg, R. Kobos, A. Krishnan. "Teclistamab, a BCMA×CD3 Antibody, in Triple-Class Exposed Multiple Myeloma", New England Journal of Medicine, June 2022
- P. Moreau, **S. Girgis**, J. D. Goldberg. "Teclistamab in relapsed or refractory multiple myeloma". Response to letter to Editor, NEJM, 2022
- S. Usmani, A. Garfall, N W. van de Donk, H. Nahi, J F. San-Miguel, A Oriol, L Rosinol, A Chari, M. Bhutani, L. Pei, R. Verona, **S. Girgis**, T. Stephenson, J D. Goldberg, A. Banerjee, M V. Mateos, AY. Krishnan. "Teclistamab, a BCMA×CD3 bispecific antibody, in pretreated multiple myeloma", The Lancet, 398(10301), Aug 2021
- C. Drake, R. Pachynski, S. Subudhi, D. McNeel, E. Antonarakis, T. Bauer, D. Patricia, M. Wade, E. Zudaire, N. Bandyopadhyay, D. Parasrampur, **S. Girgis**, D. Wariabharaj, G. Mason, R. Knoblauch, N. Stone, J. Infante, M. Gottardis, L. Fong, "Safety and preliminary immunogenicity of JNJ-64041809, a live attenuated, double-deleted listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer", Prostate Cancer Prostatic Diseases, s41391-021-00402-8, Jul 2021
- N. Di Prospero, J. Gambale, G. Pandina, L. Ford, **S. Girgis**, J. Moyer, L. Xi, J. Nye, D. Kasteleijn-Nolst Trenite. "Evaluation of JNJ-26489112 in patients with photosensitive epilepsy: a placebo-controlled, exploratory study", Epilepsy Research, 108(4), 2014
- P. Moreau, I. Karamanesht, N. Domnikova, M. Kyselyova, K. Vilchevska, V. Doronin, A. Schmidt, C. Hulin, X. Leleu, D. Esseltine, K. Venkatakrishnan, D. Skee, H. Feng, **S. Girgis**, A. Cakana, H. van de Velde, W.

Deraedt, Facon T. "Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma", *Clinical Pharmacokinetics*, 51(12), 2012

- A. Hellmann, S. Rule, J. Walewski, O. Shpilberg, H. Feng, H. van de Velde, H. Patel, D. M. Skee, **S. Girgis**, V. J. Louw. "Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma and non-hodgkin's lymphoma", *Clinical Pharmacokinetics*, 50(12), 2011
- P. Moreau, H. Pylypenko, S. Grosicki, I. Karamanesht, X. Leleu, M. Grishunina, G. Rekhman, Z. Masliak, T. Robak, A. Shubina, B. Arnulf, M. Kropff, J. Cavet, D. Esseltine, H. Feng, **S. Girgis**, H. van de Velde, W. Deraedt, J. Harousseau. "Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study", *Lancet Oncology* (11) 2011
- C. Patel, L. Li, **S. Girgis**, D. Kornhauser, E. Frevert, D. Boulton. "Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole", *Clinical Pharmacology: Advances and applications*, vol. 2, 2011
- S. M. Pai, **S. Girgis**, V. K. Batra and I. G. Girgis. "Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates", *AAPS journal*, vol.11, 2009
- **S. Girgis**, S.M. Pai, I.G. Girgis and V.K. Batra. "Pharmacodynamic parameter estimation: population size versus number of samples", *AAPS journal*, vol.7, 2005 (in memory of Dr. Sheiner)
- X. Miao, L. S. Wu, SX. Wang Lin, Y. Xu, Y. Chen, Y. Iwaki, R. Kobos, T. Stephenson, K. Kemmerer, C. M. Uhlar, A. Banerjee, J. D. Goldberg, D. Trancucci, A. Apte, R. Verona, L. Pei, R. Desai, K. Hickey, Y. Su, D. Ouellet, M. N. Samtani, Y. Guo, A. L. Garfall, A. Krishnan, S. Z. Usmani, H. Zhou, **S. Girgis**. "Population pharmacokinetics and exposure–response with teclistamab in patients with relapsed/refractory multiple myeloma: results from MajesTEC-1", accepted for publication
- M.E. Willemin, SX. Wang Lin, L. De Zwart, L. S. Wu, X. Miao, R. Verona, A. Banerjee, B. Liu, R. Kobos, M. Qi, D. Ouellet, J. D. Goldberg, **S. Girgis**. "Evaluation of drug interaction potential as a result of cytokine release syndrome using a physiologically based pharmacokinetic model: a case study of teclistamab" in preparation

Selected Abstracts & Presentations

- X. Ma, J. Gong, J. Zhou, D. Yuan, D. Vishwamitra, B. Hilder, T. J. Masterson, J. A. Tolbert, T. Renaud, C. Heuck, C. Kane, M. N. Samtani, **S. Girgis**, J. G. Berdeja, A. Y. Krishnan, D. Ouellet. "Efficacy, safety, pharmacokinetic, and pharmacodynamic support for talquetamab QW and Q2W dosing in patients with relapsed/refractory multiple myeloma: analyses from MonumentAL-1", poster presentation at ASCO Annual Meeting, June 2023
- M.E. Willemin, SX. Wang Lin, L. De Zwart, L. S. Wu, X. Miao, R. Verona, A. Banerjee, B. Liu, R. Kobos, M. Qi, D. Ouellet, J. D. Goldberg, **S. Girgis**. "Drug interaction potential as a result of cytokine release syndrome using a physiologically based pharmacokinetic model: case study of teclistamab, poster presentation at ASH Annual Meeting, Dec 2022

- X. Miao, L. S. Wu, SX. Wang Lin, Y. Xu, Y. Chen, Y. Iwaki, R. Kobos, T. Stephenson, K. Kemmerer, C. M. Uhlar, A. Banerjee, J. D. Goldberg, D. Trancucci, R. Verona, L. Pei, Y. Su, D. Ouellet, A. L. Garfall, A. Krishnan, S. Z. Usmani, **S. Girgis**, H. Zhou. “Teclistamab population pharmacokinetics and exposure–response relationship support 1.5 mg/kg dose regimen in relapsed/refractory multiple myeloma”, poster presentation at ASH Annual Meeting, Dec 2022

- D. Cortes-Selva, T. Casneuf, D. Vishwamitra, S. Stein, T. Perova, S. Skerget, E. Ramos, L. Van Steenbergen, D. De Maeyer, R. Boominathan, O. Lau, C. Davis, A. Banerjee, T. Stephenson, C. Uhlar, R. Kobos, J. D. Goldberg, L. Pei, D. Trancucci, **S. Girgis**, SX. Wang Lin, L. S. Wu, P. Moreau, S. Z. Usmani, N. J. Bahlis, N. WCJ van de Donk, R. Verona. “Teclistamab, a BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: correlative analyses from MajesTEC-1”, oral presentation at ASH Annual Meeting, Dec 2022

- A. Nooka, P. Moreau, S Z. Usmani, A. Garfall, N W. van de Donk, J F. San-Miguel, A. Oriol, L. Karlin, M V. Mateos, R. Popat, J. Martínez-López, S. Sidana, D. Trancucci, R. Verona, **S. Girgis**, C. Uhlar, T. Stephenson, A. Banerjee, A. Krishnan. “Teclistamab, a BCMA x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Updated efficacy and safety results from MajesTEC-1”, oral presentation at ASCO Annual Meeting, May 2022

- C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, **S. Girgis**, C. Uhlar, R. Kobos, A. Garfall. “Efficacy and safety of teclistamab, a BCMA x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents”, poster presentation at ASCO Annual Meeting, Jun 2022.

- **S. Girgis**, S X. Wang Lin, K. Pillarisetti, R. Verona, D. Vieyra, T. Casneuf, D. Fink, X. Miao, Y. Chen, T. Stephenson, A. Banerjee, B. Hilder, J. Russell, J. Smit, J D. Goldberg. “Teclistamab and Talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma”, poster presentation at ASCO Annual Meeting, Jun 2021.
 - *This work was also presented at EHA in June 2021, ESH in Sept 2021 (Multiple Myeloma: Targeting BCMA with bispecifics and CARs, featured on Twitter) & IMW in Sept 2021*

- **S. Girgis**, S X. Wang Lin, K. Pillarisetti, A. Banerjee, J D. Goldberg, S. Shetty, T. Stephenson, B. Hilder, B. Hanna, J. Smit, H. Adams, Y. Sun, J. Infante, Y. Elsayed, A. Sharma. “Translational approach of using ex vivo cytotoxicity and early clinical data to predict Teclistamab efficacious therapeutic range in multiple myeloma patients”, poster presentation at ASH Annual Meeting, Dec 2020
 - *This work was also presented at the Janssen Research & Development Symposium, Nov 2019*

- S. Usmani, M V. Mateos, H. Nahi, AY. Krishnan, N W. van de Donk, J F. San-Miguel, A Oriol Rocafiguera, L Rosinol, A Chari, H. Adams, **S. Girgis**, S X. Wang Lin, T. Stephenson, K. Kemmerer, J. Smit, Y A. Elsayed, J R. Infante, J D. Goldberg, A. Banerjee, A L. Garfall. "Phase 1 study of Teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed and/or refractory multiple myeloma (RRMM)", oral presentation at ASCO Annual Meeting, May 2020
 - *Updated results were presented (oral) at ASH Annual Meeting, Dec 2020.*

- *Additional updated results were presented (oral) at ASCO Annual Meeting, Jun 2021.*
- *Recent updated results of MajesTEC-1 were presented (oral) at ASH Annual Meeting, Dec 2021*

- A Chari, J G. Berdeja, A. Oriol, N W. van de Donk, P. Rodriguez-Otero, E. Askari, M V. Mateos, M C. Minnema, R. Verona, **S. Girgis**, T. Prior, B W. Hilder, J. Russell, J D. Goldberg, A. Krishnan. “A phase 1, first-in-human study of Talquetamab, a G protein-coupled receptor family C group 5 member D (GPC5D) x CD3 bispecific antibody, in patients with relapsed and/or refractory multiple myeloma (RRMM)”, oral presentation at ASH Annual Meeting, Dec 2020.
 - *The updated results were presented (oral) at ASCO Annual Meeting, Jun 2021.*
 - *Additional updated results of MonumenTAL-1 were presented (oral) at ASH Annual Meeting, Dec 2021*
- W. Wang, O. Milberg, **S. Girgis**, S X. Wang lin, C. Lowenstein, Y. Sun, H. Zhou. “Development of a quantitative systems pharmacology (QSP) model for T cell redirecting bispecific antibodies for oncology indications”, poster presentation at the Janssen Quantitative Sciences Conference, Oct 2020
- E. Calvo, V. Moreno, R. Perets, T. Peretz, N. Fourneau, **S. Girgis**, Y. Guo, P. Hellemans, D. Hokey, N. Pendás, Q. Xia, R. Geva. “Phase 1 study to assess safety, pharmacokinetics and pharmacodynamics of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors”, poster presentation at ASCO Annual Meeting, Jun 2019
- **S. Girgis**, T. Salcedo, S. Shetty, T. Jiao, R. Grimme Watson, J. Ford, K. Pillarisetti, E. Baldwin, K. Bellew. “Exploratory pharmacokinetic/ pharmacodynamic and tolerability study of BCMAxCD3 in cynomolgus monkeys”, poster presentation at Janssen Oncology Annual Meeting, Mar 2016
- R. Charnas, T. Salcedo, **S. Girgis**. “Bridging strategy for toxicology and biodistribution of listeria monocytogenes immunotherapy”, poster presentation at the Janssen Oncology Annual Meeting, Mar 2016
- H. Kuan, N. Gupta, K. Venkatakrishnan, A. Milton, **S. Girgis**, I. Poggesi, D. Mould. “Population pharmacokinetic modeling of bortezomib after bolus intravenous injection in cancer patients”, poster presentation at PAGE Annual Meeting, Jun 2012
- P. Moreau, I. Karamanesht, N. Domnikova, M. Kyselyova, K. Vilchevska, A. Schmidt, C. Hulin, X. Leleu, D. Esseltine, K. Venkatakrishnan, D.M. Skee, H. Feng, **S. Girgis**, A. Cakana, W. Deraedt and T. Facon. “Pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: effects of subcutaneous Injection site and concentration, and patient characteristics”, poster presentation at ASH Annual Meeting, Dec 2011
- A. Bernard, G. Mannens, R. Connors, R. Hammond, P. De Porre, M. Acharya, **S. Girgis**. “A Phase 1 Study to determine the pharmacokinetics, metabolism and routes of excretion of [¹⁴C] radiolabeled decitabine administered over a 3-hour infusion in subjects with myelodysplastic syndrome or acute myeloid leukemia”, poster presentation at JNJ ADMET Symposium, Sept 2011
- A. Hellmann, S. Rule, J. Walewski, O. Shpilberg, H. Feng, H. van de Velde, H. Patel, D. M. Skee, **S. Girgis**, V. J. Louw. “Effect of cytochrome P450 3A4 inducers, rifampicin and dexamethasone on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma and non-hodgkin’s lymphoma”, poster presentation at ASH Annual Meeting, Dec 2010.
- W. Zhang, **S. Girgis**, S. Dorizio, M. Pfister, X. Liu, F. LaCreta, W. Shyu. “Effect of a high Fat Meal on the pharmacokinetics of dapagliflozin in healthy subjects, AAPS Journal 11 (S2), Abstract # 000857, 2009

- B. Vakkalagadda, **S. Girgis**, A. Bragat, S. Nepal, C. Maurer, C. Frost, F. LaCreta and A. Shenker. "The effect of rifampin on the pharmacokinetics of apixaban in healthy subjects", BMS Symposium, Nov 2007
- **S. Girgis**, F. Vincenti, C. Larsen, J. Grinyo, J. Shapiro, X. You, B. Vakkalagadda, J. Park, H. Dong, D. Geng, D. Nguyen, K. Soucek, U. Thienel, M. Agarwal. "Pharmacokinetics of belatacept in renal transplant patients", J. Clin Pharmacol, vol 47(9) abstract # 88, 2007, poster presentation at the American College of Clinical Pharmacology Annual Meeting, Sept 2007
- **S. Girgis**, X. You, L. Li, C. Maurer, D. Whigan, D. Boulton. "Effect of simvastatin on the pharmacokinetics of saxagliptin in healthy subjects", J. Clin Pharmacol, vol 47(9) abstract # 28, 2007, poster presentation at the American College of Clinical Pharmacology Annual Meeting, Sept 2007. Also, reported at Doctor's Guide, September 2007
- **S. Girgis**, C. Patel, L. Li, L. Gooding, U. Frevert, D. Whigan, D. Boulton. "Effect of diltiazem on the pharmacokinetics of saxagliptin in healthy subjects", J. Clin Pharmacol, vol 47(9) abstract # 72, 2007, poster presentation at the American College of Clinical Pharmacology Annual Meeting, Sept 2007
- **S. Girgis**, A. Keung, A. Sansone, M. Laughlin, M. Caceres and V. Batra. Pharmacokinetics of SCH 417690 after single oral administration in healthy adult volunteers, Pharm.Sci.Supplement, vol.5 (No.4), Abstract # M1317, 2003
- **S. Girgis**, S.M. Pai, J. Veals and V.K. Batra. "Prediction of human pharmacokinetics from pre-clinical data using the population approach", Pharm.Sci.Supplement, vol.4 (No.4), Abstract # R6232, 2002, poster presentation at the American Association of Pharmaceutical Scientists Annual Meeting, Nov 2002
- **S. Girgis**, S.M. Pai, I.G. Girgis and V.K. Batra. "How the sigmoidicity constant affects pharmacodynamic parameter estimation from sparse sampling", Clinical Pharmacology & Therapeutics, vol:71(2), 2002, poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Mar 2002
- **S. Girgis**, S.M. Pai, V.K. Batra and I.G. Girgis. "Pharmacodynamic Parameter Estimation: population size versus number of samples", Clinical Pharmacology & Therapeutics, vol:69(2), 2001, poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Mar 2001
- **S. Girgis** and S. Rosenbaum "Optimum Design for pharmacodynamics", Clinical Pharmacology & Therapeutics, vol:67(2), 2000, poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting, Mar 2000

Patents:

Teclistamab, Method for Treating Multiple Myeloma

Talquetamab, Method for Treating Multiple Myeloma